SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, announced today the receipt of additional financial support for the company’s lead oncology product, Rexin-G®, from the U.S. Departments of Treasury, Health and Human Services (HHS), and the National Institutes of Health (NIH) in the form of a prestigious competitive grant.
This latest support for the clinical advancement of Rexin-G comes from the Qualifying Therapeutic Discovery Project (QTDP) program, created as a component of the Patient Protection and Affordable Care Act of 2010 to support projects that are determined by the HSS to have significant potential (i) to develop innovative new treatments to address major unmet medical needs, (ii) to reduce long-term health care costs, (iii) to represent significant medical progress toward an eventual treatment/cure for cancer, (iv) to advance U.S. competitiveness in the fields of life science and medical technologies, and (v) to create and/or sustain well-paying jobs in the United States.
This meritorious tranche of U.S. Government support for Rexin-G, the world’s first and, so far, only targeted injectable genetic medicine for cancer that has been validated in clinical trials, represents the latest formal declaration of the potential importance, competitiveness, and overall merit of the platform of highly-advanced molecular biotechnologies and nanotechnologies embodied in this targeted injectable anticancer agent.
“We are very pleased with this formal recognition and support of our medical mission, for it represents a continuing commitment to develop the high-value products and intellectual properties of this company for the benefit of all,” said Lina Kabayan, Epeius CFO who spearheaded this latest grant submission.
From the first National Science Foundation (NSF) and NIH grants awarded to the founders of Epeius Biotechnologies, to the American Heart Association (AHA) which provided funding to support the cardiovascular targeting technologies, to the Office of Orphan Products Development (OOPD) which provided funding for the first clinical trials in the U.S., and which ultimately granted Orphan Drug Status to Rexin-G for three separate clinical indications (pancreatic cancer, soft tissue sarcoma, and osteosarcoma), to the U.S. FDA which granted Fast Track Status to Rexin-G for chemotherapy-resistant pancreatic cancer, the continuing federal support for these vital medical technologies is a testament that basic science and innovation in the service of medicine is still alive and well in America.
About Epeius Biotechnologies Corporation:
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company that is bringing the latest advancements in genetic medicine to the cancer patient with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems. Rexin-G® is currently approved for the treatment of all chemotherapy-resistant solid tumors by the Philippine FDA.
Learn more about our lead products and/or our pipeline of proprietary biotechnologies at: www.epeiusbiotech.com. For recent papers, expert reviews, clinical reports in oncology and molecular therapy, see the “Publications” section.
– Epeius Biotechnologies news RSS feed:
News issued by: Epeius Biotechnologies Corporation
Original Image: https://www.send2press.com/wire/images/10-0907-epeiusbio_72dpi.jpg
# # #
Original Story ID: (6445) :: 2010-11-1108-001
Original Keywords: targeted genetic medicine, lead oncology product, Rexin-G, orphan drug status, fda, pharma, biotech, drug research, cancer treatments, erlinda gordon, rexing, targeted injectable genetic medicine for cancer, Lina Kabayan, NIH grant Epeius Biotechnologies Corporation San Marino California SAN MARINO, Calif.
Alternate Headline: Epeius’ Rexin-G Gains U.S. Government Support as Therapeutic Discovery Project
NEWS ARCHIVE NOTE: this archival news content, issued by the news source via Send2Press Newswire, was originally located in the Send2Press® 2004-2015 2.0 news platform and has been permanently converted/moved (and redirected) into our 3.0 platform. Also note the story “reads” counter (bottom of page) does not include any data prior to Oct. 30, 2016. This press release was originally published/issued: Mon, 08 Nov 2010 11:47:57 +0000
News Source: Epeius Biotechnologies Corporation